Achaogen Inc.

Achaogen Inc. is a clinical stage biopharmaceutical company specializing in the discovery and development of broad-spectrum antibiotics to combat multidrug resistant bacterial infections. The company offers a range of small molecule therapeutics and is actively involved in compound discovery, lead optimization, and early-stage clinical trials. Achaogen's focus is on addressing medical needs stemming from bacterial resistance to antibiotics, and it operates a research facility in San Francisco. The company receives non-dilutive funding from the Department of Defense and the Welcome Trust, and has developed ACHN-490 and other neoglycosides to overcome aminoglycoside resistance mechanisms. Additionally, Achaogen administers several preclinical programs.